Angiogenesis plays a key role in tumor development and α v β 3 integrin are overexpressed on the endothelial cell surface of newly forming vessels.
Preoperative staging of mediastinal lymph nodes (MLNs) provides accurate information on the extent of non-small cell lung cancer (NSCLC), it determines the prognosis and guides the choice of therapeutic modalities, consequently is of great importance for patients with NSCLC 1 . As a result, the demand for noninvasive imaging is increased to promote MLN-staging accuracy in NSCLC patients. 18 F-AlF-NOTA-PRGD 2 ( 18 F-Alfatide), a novel tracer targeting integrin α v β 3 , has been studied for angiogenesis imaging by positron emission tomography (PET) 2, 3 . The growth of neovascularization from preexisting ones is called angiogenesis and angiogenesis is a major way in tumor growth and metastases 4 . In the integrin family, one of the most critical molecules involving in tumor angiogenesis and metastases is integrin receptor α v β 3 5, 6 . The integrin α v β 3 which from a class of transmembrane glycoproteins consisting of 18α-and 8β-subunits is researched the most widely and is significantly up-regulated in activated endothelial cells of tumors undergoing angiogenesis, but not expressed in normal cells and quiescent vessel cells 3, 4, 7 . Therefore, tumor angiogenesis can be evaluated by imaging α v β 3 expression, making the integrin receptor α v β 3 a valuable target for diagnosing malignant tumors and metastases 3 . The various modifications of cyclic arginine-glycine-aspartic acid (RGD) . In a previous clinical study, this new tracer, 18 F-Alfatide, is safe when used in the human body and possibly valid in diagnosing primary tumors in patients with NSCLC 3 . Therefore, 18 F-Alfatide was used as a novel tracer for integrin α v β 3 PET/CT examination in this present research. The objective was to detect lymph node metastases (LNMs) in patients with NSCLC, and to conduct a pilot research of 18 F-Alfatide PET/CT diagnostic ability in the imaging of mediastinal LNMs in patients with NSCLC.
Results
After the examination of 18 F-Alfatide PET/CT, no clinically detectable pharmacologic effects or adverse reactions were observed in any of these subjects. There were no marked changes in laboratory values or vital signs.
Twenty of the resected 196 lymph nodes (10.2%) were malignant in patients with NSCLC, six of 104 lymph nodes were malignant in patients with adenocarcinoma (AC) and 5 of the resected 65 lymph nodes were malignant in patients with squamous cell carcinoma (SCC). All the metastatic lymph nodes could clearly be delineated visually among the resected lymph nodes on the 18 F-Alfatide PET/CT images. Receiver operating characteristic (ROC) curves for semi-quantitative assessment were illustrated by Fig. 1(a,b,c) . Figure 2 the upper row provides an example of lymph node metastasis proved by gold standard and the lower row provides a false positive example.
Lymph Nodes in NSCLC. Visual assessment. Using 18 F-Alfatide, 20 lymph nodes were correctly recognized in accordance with pathological results and 9 were incorrectly found. Corresponding sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and accuracy were 100.0%, 94.9%, 100.0%, 69.0% and 95.4%.
Semi-quantitative assessment. Using 18 F-Alfatide, malignant lymph nodes (median, 2.15; range, 1.1 to 3.8) had significantly higher maximum standardized uptake value (SUV max ) (P < 0.001) than benign lymph nodes (median, 0.9; range, 0.3 to 3.3) in patients with NSCLC. The same result was obtained for average SUV (SUV mean ) in distinguishing between malignant lymph nodes (median, 1.7; range, 0.9 to 2.5) and benign lymph nodes (median, 0.8; range, 0.3 to 2.6; P < 0.001). Table 1 shows statistically significant differences between benign and malignant lymph nodes for SUV max , SUV mean , and SUV ratios.
The optimal cut-off values of SUV max and SUV mean were >1.4 and >1.2 by the ROC analyses ( Fig. 1a ; Table 2 ) and their respective areas under the curve (AUCs) were 0.95(95% confidence interval [CI], 0.91 to 0.98) and 0.94 (95% CI, 0.90 to 0.97), respectively. All results are represented in Table 3 .
Subgroups of NSCLC.
Visual assessment of lymph nodes in AC. 11 lymph nodes (10.6%) in patients with AC were recognized visually and six of them (54.5%) were confirmed as pathologically malignant, while five of the 11 lymph nodes (45.6%) were proven to be false positive. Corresponding sensitivity, specificity, NPV, PPV and accuracy were 100.0%, 94.9%, 100.0%, 54.6% and 95.2% (Table 4) .
Semi-quantitative assessment of lymph nodes in AC.
Using 18 F-Alfatide, the malignant lymph nodes (median, 1.8; range, 1.1 to 3.8) has significantly higher SUV max (P < 0.001) than in benign lymph nodes (median, 0.95; range, 0.3 to 2.5). The same result was obtained for the SUV mean in distinguishing between malignant lymph nodes (median, 1.45; range, 0.9 to 2.5) and benign lymph nodes (median, 0.9; range, 0.3 to 1.8; P < 0.001). Table 1 shows statistically significant differences between benign and malignant lymph nodes for SUV max , SUV mean , and SUV ratios. The optimal cut-off values of SUV max and SUV mean were >1.4 and >1.1 by the ROC analyses ( Fig. 1b ; Table 2 ) and their AUCs were 0.86 (95% CI, 0.78 to 0.92) and 0.83 (95% CI, 0.75 to 0.90), respectively. All results are represented in Table 4 .
Visual assessment of lymph nodes in SCC. 9 lymph nodes (13.8%) in patients with SCC were recognized visually and five of them (55.6%) were confirmed as pathologically malignant, while four of the 9 lymph nodes (44.4%) Table 1 . Characteristics of lymph node stations at 18 F-Alfatide PET/CT. All data represent median (range). NSCLC, non-small cell lung cancer; AC, adenocarcinoma; SCC, squamous cell carcinoma; P, P value; SUV, standardized uptake value; LN, lymph node; MBP, mediastinal blood pool; PT, primary tumor; M, muscle. Table 2 . Receiver operating characteristic analysis: area under the curves and optimal cut-off values. CI, confidence interval; SUV, standardized uptake value; LN, lymph node; MBPS, mediastinal blood pool; PT, primary tumor; M, muscle; P, P value.
were proven as false positive. Corresponding sensitivity, specificity, PPV, NPV and accuracy were 100.0%, 93.3%, 55.6%, 100.0% and 93.9% (Table 5) .
Semi-quantitative assessment of lymph nodes in SCC.
The malignant lymph nodes (median, 1.7; range, 1.4 to 2.2) had significantly higher SUV max (P < 0.001) than benign lymph nodes (median, 0.9; range, 0.4 to 3.3). The same result was obtained for SUV mean in distinguishing between malignant lymph nodes (median, 1.3; range, 1.1 to 1.8) and benign lymph nodes (median, 0.8; range, 0.4 to 2.6; P < 0.001).
The optimal cut-off values of SUV max and SUV mean were >1.3 and >1.0 by the ROC analyses ( Fig. 1c ; Table 2 ) and their AUCs were 0.98 (95% CI, 0.91 to 1.0) and 0.98 (95% CI, 0.90 to 1.0), respectively. All results are represented in Table 5 .
Discussion
This is a pilot clinical research to evaluate the prognostic value of the 18 F-Alfatide PET/CT in detecting mediastinal LNMs in patients with NSCLC. This new tracer, 18 F-Alfatide, has been again proven safe when used in clinical trials, is convenient in the synthesis process, and has shown a significant diagnostic value of mediastinal LNMs.
FDG PET/CT is widely used for detecting LNMs in patients with NSCLC. In a previous meta-analysis, mean sensitivity and specificity of FDG PET/CT for LNMs detection were 69% and 95% 23 . The FDG PET/CT had a relatively high specificity with low sensitivity 24 and the results were barely satisfactory. Therefore, the researchers focused their attention on the development of new diagnostic methods and new tracers of PET for detecting LNMs in patients with NSCLC. In the previous study, the accuracy of 11 C-choline PET/CT of LNMs detection was 83.76% and the sensitivity was 100%. These results seem to be encouraging, but specificity (72%) was not good enough for diagnosing LNMs in patients with NSCLC 25, 28 . Yamamoto et al. 26 indicated that the diagnostic ability of FLT PET was lower than FDG PET, the sensitivity, specificity, PPV, NPV and accuracy of FLT PET and FDG PET for lymph node staging were 57%, 93%, 67%, 89%, 85 and 57%, 78%, 36%, 91%, 74%, respectively. For 4DST, the results of clinical study suggested that the sensitivity for detecting LNMs was high (82%), but its low specificity (72%) was a limitation (P < 0.001) 27 . Compared with FGD PET/CT and other tracers PET/CT, 18 F-Alfatide PET/CT showed significantly high sensitivity (85-100%) and specificity (81.2-96.0%) for detecting mediastinal LNMs in patients with NSCLC. The sensitivity, specificity, PPV, NPV and accuracy of 18 F-Alfatide PET/CT visual analysis were 100%, 94.9%, 69%, 100% and 95.4%, respectively.
Invasive surgical examinations, such as endobronchial ultrasonography transbronchial needle aspiration (EBUS-TBNA) 29 and mediastinoscopy, showed high specificity and sensitivity for lymph node staging. However, these tests are invasive, and lesion location may restrict the possibility of obtaining tissue samples. 18 F-Alfatide PET/CT imaging is noninvasive and showed significantly high sensitivity and specificity for detecting mediastinal LNMs in patients with NSCLC. Among all 18 F-Alfatide PET semi-quantitative parameters, the SUV max showed a better performance and has the potential to serve as the most important semi-quantitative parameter to improve noninvasive nodal staging and treatment planning for LNMs after use of 18 F-Alfatide PET/CT scans. Angiogenesis is a vital process in tumor progression and tumor growth, and it is responsible for the metastasis of lymph nodes. Previous work suggests that high expression of integrin α v β 3 on the endothelial cells surface of angiogenesis is related to its proliferative and metastatic properties [30] [31] [32] . Therefore, 18 F-Alfatide is very sensitive to the growth and metastasis of tumors. The high sensitivity of visual and SUV max (Tables 3, 4 and 5) for LNMs indicates that it may be detecting micro node metastases.
In this present study, seven AC cases (54%) and 4 SCC cases (31%) were included, and they showed a similar visual and semi-quantitative analysis outcome as the results from NSCLC patients. Even though the SUV LN/PT was low in both AC and SCC, they did not show significant differences when compared with SUV mean , SUV LN/MBP and SUV LN/M (P > 0.05).
18 F-Alfatide PET/CT imaging showed a high sensitivity of SUV max in patients with NSCLC (90.0%) and SCC (100%) but relatively low sensitivity (83.3%) in patients with AC. It is reported that AC is known for low FDG-avidity 33 and AC may have low affinity with 18 F-Alfatide as well. This may explain the low sensitivity in AC. 18 F-Alfatide PET/CT imaging appears to merit LNMs assessment, which is very important for clinical decision-making and surgical planning for NSCLC patients. Even though it has excellent results for lung cancer staging, 9 false-positives occurred in the present study. False-positive uptake was caused by chronic inflammatory and the inflammatory process often accompanying angiogenesis, which produces a large amount of integrin α v β 3 3 . The accuracy (95.4%; 95.2%; 93.9%) of visual analysis was similar with SUV max (95.4%; 94.2%; 96.9%) in patients with NSCLC, AC and SCC. It is also of note that the simpler visual analysis is preferred and SUV would be a secondary aid.
The results indicated that 18 F-Alfatide PET/CT imaging is potentially successful in diagnosing metastatic lymph nodes with a high sensitivity and specificity in patients with NSCLC. Even though the outcome of this present study is promising, the number of patients was small. Supplementary researches with a larger number of patients would be requested to confirm the results.
Methods
Thirteen patients including 196 assessable lymph nodes were analyzed (male, n = 6; female, n = 7; median age, 57 years [range, 45 to 69 years]). The including criteria: (1) histologically proven NSCLC, (2) all patients performed lobectomy + lymph node dissection surgery after 18 F-Alfatide PET/CT imaging, (3) histological results of lymph nodes were available as the gold standard for diagnosis, (4) the age >18 years. Patients histological subtypes included SCC (n = 4), AC (n = 7) and NSCLC not otherwise specified (n = 2). Patient characteristics are represented in Table 6 .
Approvals. This study was approved by the ethics committee of Shandong Cancer Hospital, and all patients provided written informed consent which included information on radiation exposure. All methods were carried out in accordance with relevant guidelines and regulations.
18 F-Alfatide PET/CT imaging. All patients underwent an 18 F-Alfatide PET/CT scan using an integrated PET/CT system (Discovery LS; GE Healthcare) from June 2013 to December 2016, which consisted a full-ring dedicated PET of and a spiral CT scan of the same axial range. We purchased PRGD2 peptide that could label with lyophilized kits simply from the Jiangsu Institute of Nuclear Medicine, and the synthesis process was carried out as previous studies 2, 3 . The patients would perform 18 F-Alfatide PET/CT scan without fasting or receiving CT contrast agents. The radiochemical purity of the 18 F-Alfatide was higher than 95% after extraction, and its specific radioactivity was higher than 37 GBq (1000 mCi)/μmol. All patients would rest for approximately 60 minutes after injecting Image analysis. PET data was reconstructed using the ordered-subsets expectation maximization algorithm. The SUV was calculated according to the following formula: (measured activity concentration [Bq/ mL] × body weight [g])/injected activity (Bq). Standard visual image interpretation and semi-quantitative analysis were conducted independently by 2 experienced nuclear medicine physicians who were blinded to the clinical and structural imaging findings. All the regions of interest were contoured separately and the SUV max & SUV mean of primary tumor, LNs, aorta and muscle were calculated. The increased 18 F-Alfatide uptake regions were defined as positive when it showed definite uptake and not related to normal physiologic uptake. And the increased 18 F-Alfatide uptake area was defined as negative when it was related to the physiologic biodistribution of 18 F-Alfatide. Care was taken to exclude adjacent blood vessels. SUV ratios of lymph nodes to primary tumor, mediastinal blood pool and muscle were calculated by SUV LN Pathological analysis. All of the patients underwent lobectomy + lymph node dissection surgery. All resected lymph nodes were marked by surgeons during the surgery according to Mountain and Dresler 1 . The tumor specimens were performed according to standard protocols as previously 3 . All hematoxylin-eosin staining tissue sections were reviewed by two pathologists who were blinded to image outcomes and arrived at a single, final conclusion between them. The pathological results were used as gold standard.
Statistical analysis. Statistical analyses were performed using the MedCalc software (MedCalc ® , version 15.2.2, 64-bit, MedCalc Software bvba, Ostend, Belgium). All semi-quantitative data are expressed as the median (range). Differences were considered statistically significant when two-tailed P values were less than 0.05. The significant differences between malignant and benign lymph nodes were tested by the Mann-Whitney U test for SUV max , SUV mean , SUV LN/PT , SUV LN/MBP and SUV LN/M . The diagnostic performance of SUV parameters in differentiating malignant from benign LNs was analyzed using the ROC curves and AUCs with their 95% CIs. The optimal cut-off values of these variables producing maximum sensitivity plus specificity were determined from ROC analyses. The nonparametric method proposed by DeLong et al. 34 was used to compare correlated ROC curves by MedCalc software. Table 6 . Patients information and diagnosis (n = 13). NSCLC, non-small cell lung cancer; AC, adenocarcinoma; SCC, squamous cell carcinoma; NOS, not otherwise specified.
